1.06
-0.05 (-4.5%)
-0.05 (-4.5%)
Upgrade to Real-Time
Afterhours
| Volume | 808,848 |
|
|||||
| News | - | ||||||
| Day High | 1.12 | Low High |
|||||
| Day Low | 1.05 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Curis Inc | CRIS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.05 | -4.5% | 1.06 | 18:07:59 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.11 | 1.05 | 1.12 | 1.06 | 1.11 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,835 | 808,848 | $ 1.08 | $ 871,290 | - | 0.70 - 9.04 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:15:01 | 20 | $ 1.09 | USD |
Period:
Draw Mode:
Curis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 97.32M | 91.81M | 91.56M | $ 10.65M | $ - | -0.50 | -1.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 2.50% |
Curis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRIS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.04 | 1.21 | 0.9406 | 1.07 | 1,552,343 | 0.02 | 1.92% |
| 1 Month | 1.16 | 1.33 | 0.85 | 1.06 | 1,717,200 | -0.10 | -8.62% |
| 3 Months | 0.766 | 1.33 | 0.70 | 0.9882597 | 3,135,796 | 0.294 | 38.38% |
| 6 Months | 3.52 | 3.61 | 0.70 | 1.46 | 2,702,194 | -2.46 | -69.89% |
| 1 Year | 7.56 | 9.04 | 0.70 | 2.95 | 2,122,877 | -6.50 | -85.98% |
| 3 Years | 1.96 | 17.40 | 0.62 | 5.46 | 2,253,313 | -0.90 | -45.92% |
| 5 Years | 9.30 | 17.40 | 0.60 | 5.11 | 1,692,766 | -8.24 | -88.6% |
Curis Description
| Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |